The role of fluoxetine hydrochloride in causing our patient's clinical, physiologic, radiologic, and pathologic abnormalities is secured by the following: (1) histologic7 and cytologic5'8 findings consistent with hypersensitivity pneumonitis; (2) the temporal correlation of symptom onset with fluoxetine hydrochloride, therapy initiation, symptom relief with drug therapy discontinuation, recrudescence with rechallenge, and eventual progression to a chronic disease requiring corticosteroids; and (3) the exclusion of other etiologies.
The lamellar inclusions we observed in macrophages resemble those seen with amiodarone.2'4'5 The clinical importance of these inclusions in the pathogenesis of the patient's pulmonary disease is uncertain, but as with amiodarone, these changes may reflect drug use, and not necessarily drug toxicity. 4 In view of fluoxetine hydrochloride's increasing use throughout the world, it is important to note the association of a pulmonary disease with this drug. To our knowledge, this is the first report establishing clinicopathologic and roentgenologic documentation of a fluoxetine hydrochloride-associated pulmonary alveolitis. In addition, pulmonary phospholipidosis was found. These two processes may or may not be related. Further studies will be needed to define the relationships between the phospholipidosislike changes described, drug dosage, and pulmonary symptoms. REFERENCES Dr. Festen is in private practice in Dordrecht.
- to instruct the patient to consult a physician when he develops persistent chest pain and to insist that he should refrain from smoking during use of the nicotine patch. Since only epidemiologic studies will clarify whether there is an increased risk of cardiovascular events associated with use of the nicotine patch, we recommend the performance of such postmarketing studies.
